Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | — | 1 | 1 | — | — | 1 |
Hepatocellular carcinoma | D006528 | — | C22.0 | — | 1 | 1 | — | — | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
T-cell lymphoma peripheral | D016411 | — | — | 1 | 13 | — | — | — | 14 |
T-cell lymphoma | D016399 | — | — | 1 | 13 | — | — | — | 14 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 12 | — | — | — | 12 |
Cholangiocarcinoma | D018281 | — | C22.1 | 2 | 10 | — | — | 2 | 12 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 4 | 9 | — | — | 2 | 11 |
Drug therapy | D004358 | — | — | 1 | 5 | — | — | 2 | 8 |
Uterine cervical neoplasms | D002583 | — | — | 2 | 7 | — | — | 1 | 8 |
Biliary tract neoplasms | D001661 | — | C24.9 | 1 | 6 | — | — | 1 | 7 |
Healthy volunteers/patients | — | — | — | 4 | 4 | — | — | — | 6 |
Chemoradiotherapy | D059248 | — | — | 1 | 5 | — | — | 1 | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Osteosarcoma | D012516 | — | — | 1 | — | — | — | — | 1 |
Adenocarcinoma of lung | D000077192 | — | — | 1 | — | — | — | — | 1 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 2 | 2 |
Hepatitis b | D006509 | — | — | — | — | — | — | 2 | 2 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 2 | 2 |
Hepatitis | D006505 | — | K75.9 | — | — | — | — | 2 | 2 |
Chronic hepatitis | D006521 | — | K73.9 | — | — | — | — | 2 | 2 |
Catheter ablation | D017115 | — | — | — | — | — | — | 2 | 2 |
Female genital neoplasms | D005833 | — | — | — | — | — | — | 1 | 1 |
Abdominal neoplasms | D000008 | — | — | — | — | — | — | 1 | 1 |
Meningioma | D008579 | EFO_0003098 | D32.9 | — | — | — | — | 1 | 1 |
Venous thrombosis | D020246 | — | I82.40 | — | — | — | — | 1 | 1 |
Drug common name | Sintilimab |
INN | sintilimab |
Description | Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease, and has been approved in China.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 2072873-06-2 |
RxCUI | — |
ChEMBL ID | CHEMBL4297829 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB15765 |
UNII ID | 8FU7FQ8UPK (ChemIDplus, GSRS) |